Tamper resistant dosage form comprising an adsorbent and an adverse agent

Patent metadata

Field	Value
Publication number	US-9795681-B2
Application number	US-201414206112-A
Country	US
Kind code	B2
Filing date	Mar 12, 2014
Priority date	Mar 30, 2004
Publication date	Oct 24, 2017
Grant date	Oct 24, 2017

Abstract

Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms.

First claim

What is claimed is:

1. A dosage form comprising an active agent, an adsorbent and an adverse agent, wherein the active agent is an opioid agonist and the adverse agent is an opioid antagonist, wherein the adsorbent comprises at least one material selected from the group consisting of an activated carbon and activated graphite, and wherein a majority of the adverse agent is adsorbed onto the adsorbent.

2. The dosage form of claim 1 , wherein at least 80 wt. % of the adverse agent is adsorbed onto the adsorbent.

3. The dosage form of claim 2 , wherein at least 90 wt. % of the adverse agent is adsorbed onto the adsorbent.

4. The dosage form of claim 1 , wherein the adsorbent is activated charcoal.

5. The dosage form of claim 1 , further comprising at least one hydrophobic material disposed at least on a portion of the outer surface of the adsorbent.

6. The oral dosage form of claim 5 , wherein the at least one hydrophobic material is selected from the group consisting of acrylic and methacrylic acid polymers and copolymers, alkylcelluloses, natural and synthetic waxes, water insoluble waxes, fatty alcohols, fatty acids, hydrogenated fats, fatty acid esters, fatty acid glycerides, hydrocarbons, hydrophobic and hydrophilic polymers having hydrocarbon backbones, and mixtures of any two or more of the foregoing.

7. The dosage form of claim 6 , wherein the at least one hydrophobic material is selected from the group consisting of glyceryl monosteareate; beeswax; cetyl alcohol; stearyl alcohol; hydrogenated castor oil; hydrogenated cottonseed oil; stearyl alcohol; stearic acid; and mixtures of any two or more of the foregoing.

8. The dosage form of claim 1 , wherein the dosage form is an oral dosage form.

9. The dosage form of claim 1 , wherein the dosage form releases about 0.5 mg or less of the adverse agent in vivo following intact administration.

10. The dosage form of claim 1 , wherein the dosage form releases about 0.05 mg or less of the adverse agent in vivo following intact administration.

11. The dosage form of claim 1 , wherein the active agent, adsorbent and adverse agent are in particulate form,
a plurality of first particles comprising the active agent; and
a plurality of second particles comprising the adsorbent and the adverse agent.

12. The dosage form of claim 11 , wherein the adsorbent is activated charcoal.

13. The dosage form of claim 11 , wherein the plurality of second particles, further comprise at least one hydrophobic material disposed on at least a portion of the outer surface of the adsorbent.

14. The dosage form of claim 13 , wherein the at least one hydrophobic material is selected from the group consisting of acrylic and methacrylic acid polymers and copolymers, alkylcelluloses, natural and synthetic waxes, water insoluble waxes, fatty alcohols, fatty acids, hydrogenated fats, fatty acid esters, fatty acid glycerides, hydrocarbons, hydrophobic and hydrophilic polymers having hydrocarbon backbones, and mixtures of any two or more of the foregoing.

15. The dosage form of claim 14 , wherein the at least one hydrophobic material is selected from the group consisting of glyceryl monosteareate; beeswax; cetyl alcohol; stearyl alcohol; hydrogenated castor oil; hydrogenated cottonseed oil; stearyl alcohol; stearic acid; and mixtures of any two or more of the foregoing.

16. The dosage form of claim 11 , wherein the opioid agonist is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metophon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, proheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, pharmaceutically acceptable salts thereof, and mixtures of any two or more of the foregoing.

17. The dosage form of claim 16 , wherein the opioid agonist is selected from the group consisting of morphine, codeine, hydromorphone, hydrocodone, oxycodone, oxymorphone, dihydrocodeine, dihydromorphine, pharmaceutically acceptable salts thereof, and mixtures of any two or more of the foregoing.

18. The dosage form of claim 1 , wherein the opioid agonist is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metophon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, proheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tramadol, tilidine, pharmaceutically acceptable salts thereof, and mixtures of any two or more of the foregoing.

19. The dosage form of claim 18 , wherein the opioid agonist is selected from the group consisting of morphine, codeine, hydromorphone, hydrocodone, oxycodone, oxymorphone, dihydrocodeine, dihydromorphine, pharmaceutically acceptable salts thereof, and mixtures of any two or more of the foregoing.

20. The dosage form of claim 1 , wherein the adsorbent comprises activated graphite.

Assignees

• Purdue Pharma Lp

Inventors

• Abreu Osvaldo

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P5/24

  of the sex hormones · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title